title: [The efficacy of the fixed drug combination dorzolamide 2%/timolol 0.5% in patients with primary open angle glaucoma].
abstract: The aim was to investigate the effectiveness of the fixed drug combination dorzolamide 2%/timolol 0.5% as monotherapy, substitutive and as adjunctive therapy in patients with primary open angle glaucoma. 130 patients were divided in three different study groups and treated by the combination dorzolamide 2%/timolol 0.5% as monotherapy, substitutive therapy and additional therapy. After three months using fixed combination dorzolamide 2%/timolol 0.5%, the mean IOP decreased by 5.6 mmHg. After prescribing substitutive therapy with fixed drug combination dorzolamide 2%/timolol 0.5% for 3 months, the intraocular preassure increased by 0.13 mmHg. Three months after the treatment with fixed combination dorzolamide 2%/timolol 0.5% as an additional antiglaucomatous drug, we have noticed a decrease of the mean IOP of 3.28 mmHg. Itching and soarness were reported by 43% patients. In conclusion, glaucoma drug therapy with fixed drug combination dorzolamide 2%/timolol 0.5% achieves effective lowering of intraocular preassure levels as monotherapy or as adjunctive therapy. As a substitutive therapy, the combination had the same IOP lowering effect. Simple drug administration and good drug tolerance indicate the effectiveness of the same drug.
authors.affiliation: Klinika za orne bolesti, KBC Split. zeljko.kovacic@kbsplit.hr
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Kovaić
authors.forename: Robert
authors.initials: R
authors.lastname: Stanić
authors.forename: Lovro
authors.initials: L
authors.lastname: Bojić
authors.forename: Veljko
authors.initials: V
authors.lastname: Rogosić
authors.forename: Milan
authors.initials: M
authors.lastname: Ivanisević
authors.forename: Karmen Stanić
authors.initials: KS
authors.lastname: Jurasin
authors.forename: Vesna
authors.initials: V
authors.lastname: Capkun
mesh_terms: D004338:Drug Combinations; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D013449:Sulfonamides; D013876:Thiophenes; C479140:dorzolamide-timolol combination; D013999:Timolol